Classifications

• • A—HUMAN NECESSITIES
  • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
  • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
  • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
  • A24B15/10—Chemical features of tobacco products or tobacco substitutes
  • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
  • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
• • A—HUMAN NECESSITIES
  • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
  • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
  • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
  • A24B15/18—Treatment of tobacco products or tobacco substitutes
  • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
  • A24B15/241—Extraction of specific substances
  • A24B15/243—Nicotine
• • A—HUMAN NECESSITIES
  • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
  • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
  • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
  • A24B15/18—Treatment of tobacco products or tobacco substitutes
  • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
• • A—HUMAN NECESSITIES
  • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
  • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
  • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
  • A24F40/05—Devices without heating means
• • A—HUMAN NECESSITIES
  • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
  • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
  • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
  • A24F40/10—Devices using liquid inhalable precursors

Definitions

• the present disclosure relates to an aerosolisable formulation, a method of forming the same, a container containing the same, a device containing the same and processes and uses of the same.
• Electronic aerosol provision systems such as e-cigarettes generally contain a reservoir of liquid which is to be vaporised, typically containing nicotine.
• a heater is activated to vaporise a small amount of liquid, which is therefore inhaled by the user.
• Aerosols from e-cigarettes and smoke from tobacco products such as cigarettes provides to the user a complex chain of flavour in the mouth, nicotine absorption in the mouth and throat, followed by nicotine absorption in the lungs.
• Nicotine contributes to a number of these factors, and is strongly associated with factors such as impact, irritation and smoothness; these are readily perceived by consumers, and e-cigarettes may offer too much or too little of these parameters for consumers, depending upon individual preferences. Nicotine reward is particularly complex as it results from both the amount of and speed with which nicotine is absorbed from the lining of the mouth, this is typically nicotine in the vapour phase, and from the amount and speed nicotine that is absorbed from the lungs, this is typically nicotine in the particulate phase of the aerosol which is inhaled. Each of these factors, and their balance, can strongly contribute to consumer acceptability of an e- cigarette. Providing means to optimise the overall vaping experience is therefore desirable to e-cigarette manufacturers. A further challenge facing such systems is the continued demand for harm reduction. Harm from cigarette and e-cigarette devices primarily comes from toxicants. Therefore, there is a desire to reduce or remove the components which may form toxicants.
• an aerosolisable formulation comprising
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation.
• a process for forming an aerosol comprising aerosolising an aerosolisable formulation comprising
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation.
• a contained aerosolisable formulation comprising
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation.
• an electronic aerosol provision system comprising:
• a power supply comprising a cell or battery for supplying power to the aerosoliser
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation.
• an aerosolisable formulation comprising (i) water in an amount of at least 50 wt.% based on the aerosolisable formulation; and (ii) nicotine; wherein the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation.
• an advantageous system may be provided in which an aerosolisable formulation contains water in an amount of at least 50 wt.% based on the aerosolisable formulation and contains nicotine in an amount of no greater than 1wt.% based on the aerosolisable formulation.
• We have surprising found that in such a high water system, providing nicotine in a maximum amount of no greater than 1wt.% provides the optimum sensory perception for the user.
• control of nicotine to this maximum amount provides a nicotine‘hit’ and/or sensory perception preferred by users.
• This desirable nicotine ‘hit’ and/or flavour release is in contrast to ‘traditional’ e-liquids based on glycerol and propylene glycol which users sometimes do not use because of perceived differences in respect of nicotine‘hit’ and/or flavour release provided by tobacco based cigarettes.
• water-based system may be provided in which aerosolised formulation is formed from an aerosolisable formulation at a low temperature. This is in contrast to‘traditional’ e-cigarettes which use a heater, typically applied to liquids based on glycerol and propylene glycol to form an aerosolised formulation.
• a heater typically applied to liquids based on glycerol and propylene glycol to form an aerosolised formulation.
• the provision of such a system and the avoidance of heating may address problems of the prior art relating to the formation of toxicants. More specifically, we have identified a water-based system which, by selection of a very high water content delivers desirable nicotine‘hit’ and/or flavour release but avoids the need to use the heaters associated with prior liquids based on glycerol and propylene glycol.
• the number of components present may be reduced leading to less chance of forming breakdown products/toxicants.
• the use of water allows for the replacement of some or all of the glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof typically used in e-cigarettes.
• the aerosolisable formulation comprises water in an amount of at least 50 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 55 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 60 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 65 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 70 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 75 wt.% based on the aerosolisable formulation.
• water is present in an amount of at least 80 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 85 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 90 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 95 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of at least 99 wt.% based on the aerosolisable formulation.
• water is present in an amount of from 50 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 55 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 60 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 65 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 70 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 75 to 99 wt.% based on the aerosolisable formulation.
• water is present in an amount of from 80 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 85 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 90 to 99 wt.% based on the aerosolisable formulation. In one aspect water is present in an amount of from 95 to 99 wt.% based on the aerosolisable formulation.
• the use of water allows for the replacement of some or all of the glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof typically used in e- cigarettes.
• the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 10 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof in a combined amount of no greater than 0.01 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol, propylene glycol, 1 ,3-propane diol and mixtures thereof.
• the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 10 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 8 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol, propylene glycol, and mixtures thereof in a combined amount of no greater than 0.01 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol, propylene glycol, and mixtures thereof.
• the aerosolisable formulation contains glycerol in an amount of no greater than 10 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 8 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol in an amount of no greater than 1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains glycerol in an amount of no greater than 0.1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains glycerol in an amount of no greater than 0.01 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no glycerol.
• the aerosolisable formulation contains propylene glycol in an amount of no greater than 10 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 8 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains propylene glycol in an amount of no greater than 1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.5 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.2 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation.
• the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.1 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains propylene glycol in an amount of no greater than 0.01 wt.% based on the aerosolisable formulation or based on the aerosolisable formulation. In one aspect the aerosolisable formulation contains no propylene glycol.
• Nicotine formulations may be provided having desirable properties of flavour, impact, irritation, smoothness and/or nicotine reward for the user.
• nicotine is present in an amount of no greater than 0.9wt.% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of no greater than 0.8wt.% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of no greater than 0.7wt.% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of no greater than 0.6wt.% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of no greater than 0.5wt.% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.4wt.% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.3wt.% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.2wt.% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.15wt.% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of no greater than 0.1wt.% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.01 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 1 wt% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.15 to 1 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.8 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.8 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.8 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.8 wt% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.1 to 0.8 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.15 to 0.8 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.5 wt% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.08 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.15 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.4 wt% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.05 to 0.4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 0.4 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.15 to 0.5 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.3 wt% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.02 to 0.3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.05 to 0.3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.08 to 0.3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 0.3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.15 to 0.3 wt% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.01 to 0.3 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.25 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.2 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.01 to 0.15 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.02 to 0.15 wt% based on the total weight of the aerosolisable formulation.
• nicotine is present in an amount of from 0.05 to 0.15 wt% based on the total weight of the aerosolisable formulation. In one aspect nicotine is present in an amount of from 0.1 to 0.15 wt% based on the total weight of the aerosolisable formulation.
• nicotine may exist in unprotonated form, monoprotonated form or diprotonated form.
• the structures of each of these forms are given below.
• references in the specification to protonated form means both monoprotonated nicotine and diprotonated nicotine. Reference in the specification to amounts in the protonated form means the combined amount of monoprotonated nicotine and diprotonated nicotine. Furthermore, when reference is made to a fully protonated formulation it will be understood that at any one time there may be very minor amounts of unprotonated nicotine present, e.g. less than 1 % unprotonated.
• the formulation may comprise nicotine in protonated form. In one aspect the formulation may comprise nicotine in unprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in monoprotonated form. In one aspect the formulation comprises nicotine in unprotonated form and nicotine in diprotonated form. In one aspect the formulation comprises nicotine in unprotonated form, nicotine in monoprotonated form and nicotine in diprotonated form.
• At least 5wt% of the nicotine present in the formulation is in protonated form In one aspect at least 10wt% of the nicotine present n the formulation is in protonated form In one aspect at least 15wt% of the nicotine present n the formulation is in protonated form In one aspect at least 20wt% of the nicotine present n the formulation is in protonated form In one aspect at least 25wt% of the nicotine present n the formulation is in protonated form In one aspect at least 30wt% of the nicotine present n the formulation is in protonated form In one aspect at least 35wt% of the nicotine present n the formulation is in protonated form In one aspect at least 40wt% of the nicotine present n the formulation is in protonated form In one aspect at least 45wt% of the nicotine present n the formulation is in protonated form In one aspect at least 50wt% of the nicotine present n the formulation is in protonated form In one aspect at least 55wt% of the nicotine present n the formulation is in protonated form In one aspect
• the nicotine present in the formulation is in protonated form. In one aspect from 55 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 60 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 65 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 70 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 75 to 95 wt% of the nicotine present in the formulation is in protonated form. In one aspect from 80 to 95 wt% of the nicotine present in the formulation is in protonated form.
• Nicotine 3-(1-methylpyrrolidin-2-yl) pyridine
• Nicotine is a diprotic base with pKa of 3.12 for the pyridine ring and 8.02 for the pyrrolidine ring It can exist in pH-dependent protonated (mono- and di-) and non-protonated (free base) forms which have different bioavailability.
• the fraction of non-protonated nicotine will be predominant at high pH levels whilst a decrease in the pH will see an increase of the fraction of protonated nicotine (mono- or di- depending on the pH). If the relative fraction of protonated nicotine and the total amount of nicotine in the sample are known, the absolute amount of protonated nicotine can be calculated.
• the relative fraction of protonated nicotine in formulation can be calculated by using the Henderson-Hasselbalch equation, which describes the pH as a derivation of the acid dissociation constant equation, and it is extensively employed in chemical and biological systems.
• [B] is the amount of non-protonated nicotine (i.e. free base)
• [BH+] the amount of protonated nicotine (i.e. conjugate acid)
• the relative fraction of protonated nicotine can be derived from the alpha value of the non-protonated nicotine calculated from the Henderson-Hasselbalch equation as:
• the aerosolisable formulation further comprises an acid.
• the acid may be any suitable acid.
• the acid is an organic acid.
• the acid is a carboxylic acid.
• the acid is an organic carboxylic acid.
• the acid is selected from the group consisting of acetic acid, lactic acid, formic acid, citric acid, benzoic acid, pyruvic acid, levulinic acid, succinic acid, tartaric acid, sorbic acid, propionic acid, phenylacetic acid, and mixtures thereof.
• the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, lactic acid, sorbic acid, and mixtures thereof.
• the acid is selected from the group consisting of citric acid, benzoic acid, levulinic acid, and mixtures thereof.
• the acid is at least citric acid.
• the acid consists of citric acid.
• the acid is selected from acids having a pka of from 2 to 5. In one aspect the acid is a weak acid. In one aspect the acid is a weak organic acid.
• the acid may be present in any suitable amount. In one aspect the acid is present in an amount of no greater than 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 5 wt% based on the aerosolisable formulation.
• the acid is present in an amount of from 0.02 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 4 wt% based on the aerosolisable formulation.
• the acid is present in an amount of from 0.05 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 4 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 3 wt% based on the aerosolisable formulation.
• the acid is present in an amount of from 0.08 to 3 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 2 wt% based on the aerosolisable formulation.
• the acid is present in an amount of no greater than 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.1 to 1 wt% based on the aerosolisable formulation.
• the acid is present in an amount of no greater than 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.6 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.1 to 0.6 wt% based on the aerosolisable formulation.
• the acid is present in an amount of no greater than 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.5 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.2 wt% based on the aerosolisable formulation.
• the acid is present in an amount of from 0.01 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.02 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.2 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of no greater than 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.01 to 0.1 wt% based on the aerosolisable formulation.
• the acid is present in an amount of from 0.02 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.05 to 0.1 wt% based on the aerosolisable formulation. In one aspect the acid is present in an amount of from 0.08 to 0.1 wt% based on the aerosolisable formulation.
• the acid has a solubility in water of at least 2g/L at 20 °C. In one aspect the acid has a solubility in water of at least 5g/L at 20 °C. In one aspect the acid has a solubility in water of at least 10g/L at 20 °C. In one aspect the acid has a solubility in water of at least 20g/L at 20 °C. In one aspect the acid has a solubility in water of at least 50g/L at 20 °C. In one aspect the acid has a solubility in water of at least 100g/L at 20 °C. In one aspect the acid has a solubility in water of at least 200g/L at 20 °C.
• the acid has a solubility in water of at least 300g/L at 20 °C. In one aspect the acid has a solubility in water of at least 400g/L at 20 °C. In one aspect the acid has a solubility in water of at least 500g/L at 20 °C. In one aspect the acid has a solubility in water of at least 600g/L at 20 °C. In one aspect the acid has a solubility in water of at least 700g/L at 20 °C. In one aspect the acid has a solubility in water of at least 800g/L at 20 °C. In one aspect the acid has a solubility in water of at least 900g/L at 20 °C. In one aspect the acid has a solubility in water of at least 1000g/L at 20 °C. In one aspect the acid has a solubility in water of at least 1100g/L at 20°C.
• the amount of acid and the solubility of the acid may be selected such that a given amount of the acid will dissolve in the water.
• the amount of acid and the solubility of the acid may be selected such that a given amount of the acid will dissolve in the water.
• at 20 °C at least 20% of the acid dissolves in the water.
• at 25 °C at least 20% of the acid dissolves in the water.
• at 30 °C at least 20% of the acid dissolves in the water.
• In one aspect at 20 °C at least 35% of the acid dissolves in the water.
• at 20 °C at least 40% of the acid dissolves in the water.
• In one aspect at 20 °C at least 45% of the acid dissolves in the water.
• at 20 °C at least 50% of the acid dissolves in the water.
• at 20 °C at least 55% of the acid dissolves in the water.
• the molar ratio of acid to nicotine may be selected as desired.
• the molar ratio of acid to nicotine is from 5:1 to 1 :5.
• the molar ratio of acid to nicotine is from 4:1 to 1 :4.
• the molar ratio of acid to nicotine is from 3:1 to 1 :3.
• the molar ratio of acid to nicotine is from 2:1 to 1 :2.
• the molar ratio of acid to nicotine is from 1.5:1 to 1 :1.5.
• the molar ratio of acid to nicotine is from 1.2:1 to 1 :1.2.
• the molar ratio of acid to nicotine is from 5:1 to 1 :1.
• the molar ratio of acid to nicotine is from 4:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 3:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 2:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 1.5:1 to 1 :1. In one aspect the molar ratio of acid to nicotine is from 1.2:1 to 1 : 1.
• the total content of acid present in the formulation is no greater than 5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no greater than 1 mole equivalents based on the nicotine.
• the total content of acid present in the formulation is no less than 0.01 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.05 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.1 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.2 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.3 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.4 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.5 mole equivalents based on the nicotine. In one aspect the total content of acid present in the formulation is no less than 0.7 mole equivalents based on the nicotine.
• the aerosolisable formulation may comprise one or more flavours or flavouring components.
• flavours or flavouring components include extracts (e.g.
• the one or more flavours may be selected from the group consisting of (4-(para-)methoxyphenyl)-2-butanone, vanillin, y- undecalactone, menthone, 5-propenyl guaethol, menthol, para-mentha-8-thiol-3-one and mixtures thereof.
• the flavour is at least menthol.
• the one or more flavours may be present in any suitable amount. In one aspect the one or more flavours are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 5 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation.
• the one or more flavours are present in a total amount of no greater than 3 wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of no greater than 1wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 5wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 4wt.% based on the aerosolisable formulation.
• the one or more flavours are present in a total amount of from 0.01 to 3wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 2wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 1wt.% based on the aerosolisable formulation. In one aspect the one or more flavours are present in a total amount of from 0.01 to 0.5wt.% based on the aerosolisable formulation.
• the aerosolisable formulation contains one or more cyclodextrins, then the aerosolisable formulation contains no flavours that can be encapsulated by the one or more cyclodextrins. In one aspect, if the aerosolisable formulation contains one or more cyclodextrins, then the aerosolisable formulation contains no flavours.
• one or more cyclodextrins may or may not be present in any suitable amount in the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 12 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 10 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 9 wt.% based on the aerosolisable formulation.
• the one or more cyclodextrins are present in a total amount of no greater than 8 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 7 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 6 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 5 wt.% based on the aerosolisable formulation.
• the one or more cyclodextrins are present in a total amount of no greater than 4 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 3 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 2 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 1 wt.% based on the aerosolisable formulation.
• the one or more cyclodextrins are present in a total amount of no greater than 0.1 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.01 wt.% based on the aerosolisable formulation. In one aspect the one or more cyclodextrins are present in a total amount of no greater than 0.001 wt.% based on the aerosolisable formulation.
• the one or more cyclodextrins may be selected from the group consisting of unsubstituted cyclodextrins, substituted cyclodextrins and mixtures thereof. In one aspect at least one cyclodextrin is an unsubstituted cyclodextrin. In one aspect the one or more cyclodextrins are selected from the group consisting of unsubstituted cyclodextrins. In one aspect at least one cyclodextrin is a substituted cyclodextrin. In one aspect the one or more cyclodextrins are selected from the group consisting of substituted cyclodextrins.
• the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, substituted (a)-cyclodextrin, unsubstituted ⁇ )-cyclodextrin, substituted ⁇ )-cyclodextrin, unsubstituted (y)-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof.
• the one or more cyclodextrins are selected from the group consisting of unsubstituted ⁇ )-cyclodextrin, substituted ⁇ )-cyclodextrin, and mixtures thereof.
• the one or more cyclodextrins are selected from the group consisting of unsubstituted (a)-cyclodextrin, unsubstituted ⁇ )-cyclodextrin, unsubstituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from unsubstituted ⁇ )-cyclodextrin.
• the one or more cyclodextrins are selected from the group consisting of substituted (a)-cyclodextrin, substituted ⁇ )-cyclodextrin, substituted (y)-cyclodextrin, and mixtures thereof. In one aspect the one or more cyclodextrins is selected from substituted ⁇ -cyclodextrins. Chemical substitutions at the 2-, 3-, and 6-hydroxyl sites are envisaged, and in particular substitution at the 2-position.
• the one or more cyclodextrins are selected from the group consisting of 2- hydroxy-propyl-a-cyclodextrin, 2-hydroxy-propyl ⁇ -cyclodextrin, 2-hydroxy-propyl-y- cyclodextrin and mixtures thereof.
• the one or more cyclodextrins is at least 2- hydroxy-propyl-a-cyclodextrin.
• the one or more cyclodextrins is at least 2- hydroxy-propyl ⁇ -cyclodextrin.
• the one or more cyclodextrins is at least 2- hydroxy-propyl-y-cyclodextrin.
• 2-hydroxy-propyl derivatives of cyclodextrins such as 2-hydroxy-propyl ⁇ -cyclodextrin have increased solubility in water when compared to base cyclodextrins such as b-cyclodextrin.
• the aerosolisable formulation contains cyclodextrins in a total amount of no greater than 0.001 wt.% based on the aerosolisable formulation, such as cyclodextrins in a total amount of no greater than 1x1 O 4 wt.% based on the aerosolisable formulation, such as cyclodextrins in a total amount of no greater than 1x10 5 wt.% based on the aerosolisable formulation, such as cyclodextrins in a total amount of no greater than 1x10 6 wt.% based on the aerosolisable formulation.
• the present invention provides (1) an aerosolisable formulation comprising
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation
• cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation
• cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation
• cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
• an electronic aerosol provision system comprising: (a) an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system;
• a power supply comprising a cell or battery for supplying power to the aerosoliser
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation
• cyclodextrins are present in a total amount of from 0 to 0.001 wt.% based on the aerosolisable formulation.
• a process for forming an aerosol comprising aerosolising an aerosolisable formulation comprising
• the nicotine is present in an amount of no greater than 1wt.% based on the aerosolisable formulation.
• the aerosol may be formed by a process performed at a temperature below 60°C.ln the process the aerosol may be formed by a process performed at a temperature below 50°C. In the process the aerosol may be formed by a process performed at a temperature below 40°C. In the process the aerosol may be formed by a process performed at a temperature below 30°C. In the process the aerosol may be formed by a process performed at a temperature below 25°C. In the process the aerosol may be formed by a process which does not involve heating.
• the aerosol may be formed by applying ultrasonic energy to the aerosolisable formulation.
• the aerosol has a D50 of from 2 to 6pm.
• References in the present specification to particle size distribution, D50, D10 or D90 refer to values measured in accordance with British and European Pharmacopoeia, 2.9.31 Particle Size Analysis By Laser Light Diffraction (see BRITISH PHARMACOPOEIA COMMISSION. (2014), British Pharmacopoeia. London, England: Stationery Office and COUNCIL OF EUROPE. (2013). European Pharmacopoeia. France: Council of Europe).
• the terms D50, Dv50 and Dx50 are interchangeable.
• the terms D10, Dv10 and Dx10 are interchangeable.
• the terms D90, Dv90 and Dx90 are interchangeable.
• the aerosol has a D50 of from 2.5 to 6pm. In one aspect the aerosol has a D50 of from 3 to 6pm. In one aspect the aerosol has a D50 of from 3.5 to 6pm. In one aspect the aerosol has a D50 of from 4 to 6pm. In one aspect the aerosol has a D50 of from 4.5 to 6pm. In one aspect the aerosol has a D50 of from 5 to 6pm. In one aspect the aerosol has a D50 of from 2.5 to 5.5pm. In one aspect the aerosol has a D50 of from 3 to 5.5pm. In one aspect the aerosol has a D50 of from 3.5 to 5.5pm. In one aspect the aerosol has a D50 of from 4 to 5.5pm. In one aspect the aerosol has a D50 of from 4.5 to 5.5pm. In one aspect the aerosol has a D50 of from 5 to 5.5pm.
• the aerosol has a D10 of at least 0.5pm. In one aspect the aerosol has a D10 of at least 1 pm. In one aspect the aerosol has a D10 of at least 2pm.
• the aerosol has a D90 of no greater than 15pm. In one aspect the aerosol has a D90 of no greater than 12pm. In one aspect the aerosol has a D90 of no greater than 10pm.
• D50 is measured after exclusion of particles having a particle size of less than 1 pm. In one aspect D10 is measured after exclusion of particles having a particle size of less than 1 pm. In one aspect D90 is measured after exclusion of particles having a particle size of less than 1 pm.
• the formulation may be contained or delivered by any means.
• the present invention provides a contained aerosolisable formulation comprising (a) one or more containers; and (b) an aerosolisable formulation as defined herein.
• the container may be any suitable container, for example to allow for the storage or delivery of the formulation.
• the container is configured for engagement with an electronic aerosol provision system.
• the container may be configured to become fluidly in communication with an electronic aerosol provision system so that formulation may be delivered to the electronic aerosol provision system.
• the present disclosure relates to container which may be used in an electronic aerosol provision system, such as an e-cigarette. Throughout the following description the term“e-cigarette” is used; however, this term may be used interchangeably with electronic aerosol provision system.
• the container of the present invention is typically provided for the delivery of aerosolisable formulation to or within an e-cigarette.
• the aerosolisable formulation may be held within an e-cigarette or may be sold as a separate container for subsequent use with or in an e-cigarette.
• e-cigarettes may contain a unit known as a detachable cartomiser which typically comprises a reservoir of aerosolisable formulation, a wick material and a heating element for vaporising the aerosolisable formulation.
• the cartomiser is part of a single-piece device and is not detachable.
• the container is a cartomiser or is part of a cartomiser.
• the container is not a cartomiser or part of a cartomiser and is a container, such as a tank, which may be used to deliver nicotine formulation to or within an e-cigarette.
• the container is part of an e-cigarette. Therefore in a further aspect the present invention provides an electronic aerosol provision system comprising: an aerosolisable formulation as defined herein; an aerosoliser for aerosolising formulation for inhalation by a user of the electronic aerosol provision system; and a power supply comprising a cell or battery for supplying power to the aerosoliser.
• the process of the present invention may comprises additional steps either before the steps listed, after the steps listed or between one or more of the steps listed.
• Figure 1 shows a graph illustrating variation of p s K a 2with nicotine concentration
• Figure 2 shows the nicotine hit, irritation and impact rating of Mojito formulation.
• The“nicotine free” device was loaded with formulation containing 88.0% (w/w) water, 6.0% propylene glycol containing vanilla flavour, and 6.0 glycerol.
• a similar device was prepared wherein 1.2% w/w nicotine was added to the formulation, with the water content was commensurately reduced to 86.8% (w/w).
• a similar device was prepared wherein 1.1% (w/w) nicotine was added to the formulation, with the water content was commensurately reduced to 96.9% (w/w).
• the summary of tested formulations and their properties are presented in the table below. Panellists were asked to evaluate the formulations in a randomised manner. During the sensory evaluation the panellists ranked several sensory attributes such as throat irritation and chest impact from low (1) to high (9). The panellists were also asked to indicate the most favourite formulation among the tested.
• the device was loaded with formulation containing 73.4% (w/w) water, 10.0% (w/w) 2- hydroxy-propyl ⁇ -cyclodextrin, 13% (w/w) glycerol 2.0% (w/w) propylene glycol containing mojito flavour, 0.8% (w/w) nicotine and 0.8% (w/w) benzoic acid.
• Nicotine hit, irritation and impact were rated and are shown in Figure 2. As can be seen from Figure 2 Mojito with 1.1 (w/w) % nicotine formulation was rated the highest for nicotine hit, irritation and impact.

Landscapes

• Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Toxicology (AREA)
• Medicinal Preparation (AREA)
• Manufacture Of Tobacco Products (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=64655549

Family Applications (1)

Country Status (13)

Families Citing this family (5)

Family Cites Families (19)

• 2018
  • 2018-11-01 GB GBGB1817859.0A patent/GB201817859D0/en not_active Ceased
• 2019
  • 2019-10-31 AU AU2019373768A patent/AU2019373768B2/en active Active
  • 2019-10-31 MX MX2021005165A patent/MX2021005165A/es unknown
  • 2019-10-31 KR KR1020217012905A patent/KR20210074308A/ko active IP Right Grant
  • 2019-10-31 US US17/290,509 patent/US20210386111A1/en active Pending
  • 2019-10-31 CN CN201980077902.6A patent/CN113163842A/zh active Pending
  • 2019-10-31 WO PCT/GB2019/053095 patent/WO2020089640A1/en unknown
  • 2019-10-31 CA CA3118060A patent/CA3118060A1/en active Pending
  • 2019-10-31 BR BR112021008571-8A patent/BR112021008571A2/pt unknown
  • 2019-10-31 UA UAA202102257A patent/UA127723C2/uk unknown
  • 2019-10-31 EP EP19798368.7A patent/EP3873248A1/en active Pending
  • 2019-10-31 JP JP2021523226A patent/JP2022506068A/ja active Pending
• 2021
  • 2021-04-22 IL IL282589A patent/IL282589A/en unknown
• 2023
  • 2023-05-19 JP JP2023082993A patent/JP2023101020A/ja active Pending

Also Published As

Similar Documents

Legal Events